28534-37-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Methoxysalicylamide is used as an active pharmaceutical ingredient for its potential anti-inflammatory and antioxidant properties, which may contribute to the treatment of various diseases such as cancer and neurodegenerative disorders.
Used in Agrochemical Industry:
5-Methoxysalicylamide is used as a key intermediate in the manufacturing of agrochemicals, contributing to the development of effective and safe products for agricultural applications.
Used in Polymer Industry:
5-Methoxysalicylamide is used as a stabilizer and inhibitor in polymer materials, enhancing the stability and performance of these materials in various applications.
It is important to handle and store 5-Methoxysalicylamide in accordance with proper safety protocols to ensure its effectiveness and safety in various applications.

InChI:InChI=1/C8H9NO3/c1-12-5-2-3-7(10)6(4-5)8(9)11/h2-4,10H,1H3,(H2,9,11)

Upstream product

• 2612-02-4 5-methoxysalicylic acid 
• 150-76-5 4-methoxy-phenol 
• 545-06-2 trichloroacetonitrile 
• 2905-82-0 methyl 5-methoxy-2-hydroxybenzoate 

Downstream Products

• 1262725-57-4 C₁₇H₁₃NO₅ 
• 1262725-56-3 C₁₇H₁₅NO₆ 
• 1257227-99-8 C₁₇H₁₃NO₅ 
• 1257227-98-7 C₁₇H₁₅NO₆ 
• 91832-81-4 5-Methoxy-2-[(1-methyl-3-pyrrolidinyl)oxy]benzamide 
• 165679-43-6 2-(2-Fluoro-phenyl)-6-methoxy-benzo[e][1,3]oxazin-4-one 
• 97960-36-6 2-allyloxy-5-methoxy-benzoic acid amide 
• 63874-34-0 2-ethoxy-5-methoxybenzamide 

Relevant academic research and scientific papers

Asymmetric Hydrogenation of Cationic Intermediates for the Synthesis of Chiral N,O-Acetals

For over half a century, transition-metal-catalyzed homogeneous hydrogenation has been mainly focused on neutral and readily prepared unsaturated substrates. Although the addition of molecular hydrogen to C=C, C=N, and C=O bonds represents a well-studied paradigm, the asymmetric hydrogenation of cationic species remains an underdeveloped area. In this study, we were seeking a breakthrough in asymmetric hydrogenation, with cationic intermediates as targets, and thereby anticipating applying this powerful tool to the construction of challenging chiral molecules. Under acidic conditions, both N- or O-acetylsalicylamides underwent cyclization to generate cationic intermediates, which were subsequently reduced by an iridium or rhodium hydride complex. The resulting N,O-acetals were synthesized with remarkably high enantioselectivity. This catalytic strategy exhibited high efficiency (turnover number of up to 4400) and high chemoselectivity. Mechanistic studies supported the hypothesis that a cationic intermediate was formed in situ and hydrogenated afterwards. A catalytic cycle has been proposed with hydride transfer from the iridium complex to the cationic sp2 carbon atom being the rate-determining step. A steric map of the catalyst has been created to illustrate the chiral environment, and a quantitative structure–selectivity relationship analysis showed how enantiomeric induction was achieved in this chemical transformation.

11C- and 18F-Labeled Radioligands for P-Glycoprotein Imaging by Positron Emission Tomography

P-Glycoprotein (P-gp) is an efflux transporter widely expressed at the human blood-brain barrier. It is involved in xenobiotics efflux and in onset and progression of neurodegenerative disorders. For these reasons, there is great interest in the assessmen

TEMPLATE HOUBEN-HOESCH REACTION ON METAL PHENOLATES. SYNTHESIS OF AROMATIC KETONES, NITRILES AND AMIDES. CRYSTAL STRUCTURE OF DICHLORO-BORON

The crystal structure of dichloro-boron (6dx) establishes for the first time the coordination mechanism of the ortho-selective reaction of metal phenolates and nitriles.Crystal data: chemical formula C9H7BCl5NO2; a = 11.743(2), b = 13.390(2), c = 8.765(3) Angstroem, β = 99.71(2) deg; space group P21/n.Variously substituted aromatic ketones, nitriles and amides have been obtained in a "one-pot" reaction.